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Accumulation of diacylglycerol (DAG), a
phospholipid precursor, is associated
with insulin resistance. Selathurai et al.
show that eliminating the CDP-
ethanolamine pathway in skeletal muscle
causes DAG accumulation and alters
membrane phospholipid composition.
However, insulin sensitivity remains
normal, and muscle mitochondrial
content, oxidative capacity, and exercise
performance are enhanced.
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Accumulation of diacylglycerol (DG) in muscle is
thought to cause insulin resistance. DG is a precursor
for phospholipids, thus phospholipid synthesis could
be involved in regulating muscle DG. Little is known
about the interaction between phospholipid and DG
in muscle; therefore, we examined whether disrupt-
ing muscle phospholipid synthesis, specifically
phosphatidylethanolamine (PtdEtn), would influence
muscle DG content and insulin sensitivity. Muscle
PtdEtn synthesis was disrupted by deleting CTP:
phosphoethanolamine cytidylyltransferase (ECT),
the rate-limiting enzyme in the CDP-ethanolamine
pathway, a major route for PtdEtn production.
While PtdEtn was reduced in muscle-specific ECT
knockout mice, intramyocellular and membrane-
associated DGwasmarkedly increased. Importantly,
however, this was not associated with insulin resis-
tance. Unexpectedly, mitochondrial biogenesis and
muscle oxidative capacity were increased in mus-
cle-specific ECT knockout mice and were accompa-
nied by enhanced exercise performance. These
findings highlight the importance of the CDP-etha-
nolamine pathway in regulating muscle DG content
and challenge the DG-induced insulin resistance
hypothesis.
INTRODUCTION
Lipids have a crucial role in biology and are essential for mainte-
nance of membrane integrity, enzyme function, cell signaling,
and energy metabolism. However, excess tissue lipid deposition
is linked to a number of pathologies, particularly insulin resis-718 Cell Metabolism 21, 718–730, May 5, 2015 ª2015 Elsevier Inc.tance and type 2 diabetes (Perseghin et al., 1999; Turner et al.,
2013). Indeed, extensive evidence demonstrates that accumu-
lation of triacylglycerol (TG) in skeletal muscle is associated
with insulin resistance (Perseghin et al., 1999). TG itself directly
interfering with insulin action is unlikely, but the general
consensus is that accumulation of bioactive lipids, particularly
diacylglycerol (DG), causes insulin resistance (Itani et al., 2002;
Li et al., 2004; Yu et al., 2002). In addition to being an important
metabolic intermediate for TG, DG is a precursor for the synthe-
sis of phospholipids. Therefore, the DG-consuming steps of
phospholipid synthesis are likely to contribute to the regulation
of intramyocellular DG. However, the interaction between phos-
pholipid and DGmetabolism in skeletal muscle has not beenwell
characterized. We therefore pursued this relationship by exam-
ining whether manipulation of phospholipid synthesis in skeletal
muscle, specifically phosphatidylethanolamine (PtdEtn), would
influence DG content and subsequently alter skeletal muscle
insulin sensitivity.
PtdEtn is the second most abundant phospholipid in mam-
mals (Bogdanov et al., 2008). The DG-consuming CDP-ethanol-
amine pathway is a major route for PtdEtn synthesis in mamma-
lian cells (Bleijerveld et al., 2007; Sundler et al., 1974), with the
rate-limiting step being the reaction catalyzed by phosphoetha-
nolamine cytidylyltransferase (ECT). The importance of PtdEtn
derived from the CDP-ethanolamine pathway is highlighted by
the fact that global knockout (KO) of ECT is embryonic lethal
(Fullerton et al., 2007). While PtdEtn has many important func-
tions in cell biology (for review see Pavlovic and Bakovic, 2013;
Vance and Tasseva, 2013), evidence is emerging to suggest
that PtdEtn synthesis via the CDP-ethanolamine pathway is
important in regulating DG levels (Leonardi et al., 2009). Specif-
ically, hepatic deletion of ECT caused DG accumulation as well
as marked liver steatosis (Leonardi et al., 2009). However, the
impact of disrupting muscle PtdEtn synthesis on DG content
and insulin sensitivity remains largely unexplored.
To examine this, we generated a conditional KO mouse with
ECT-deficient muscle. We hypothesized that elimination of
Figure 1. ECT mRNA, Protein, and Activity
(A) Genotyping of liver, kidney, and quadricepsmuscle of control (Pcyt2fl/fl,Mck-Cre0/0) and KOmice (Pcyt2fl/fl,Mck-Cre+/0). Note different brands of DNA ladders
were used for genotyping the liver and kidney versus skeletal muscle.
(B) Pcyt2 mRNA in muscle from floxed control (n = 6) and ECT KO mice (n = 6; ECT-Def.).
(C) ECT protein in control (n = 6) and ECT-deficient muscle (n = 4).
(D) ECT activity in muscle of control (n = 9) and ECT KO mice (n = 6).
(E) Immunoblot showing protein levels of phospholipid biosynthetic enzymes.
(F) Quantification of protein levels of phospholipid biosynthetic enzymes in control (n = 4) and ECT-deficient muscle (n = 4).
(G) mRNA expression of phospholipid biosynthetic genes in control (n = 5) and ECT-deficient muscle (n = 5). Data are mean ± SEM. *p < 0.05; **p < 0.01;
****p < 0.0001.ECT in muscle would cause a reduction in DG utilization via the
CDP-ethanolamine pathway, leading to DG accumulation and
muscle insulin resistance. Although the absence of ECT resulted
in a dramatic increase in muscle DG, it did not cause whole-body
or skeletal muscle insulin resistance. Surprisingly, however, we
found that mice with ECT-deficient muscle exhibited an increase
in mitochondrial biogenesis and oxidative capacity that was
accompanied by enhanced endurance exercise performance.
Thus, in addition to demonstrating that the CDP-ethanolamine
pathway plays a significant role in controlling muscle DG levels,
we have identified previously unrecognized roles for the PtdEtn
in regulating muscle function and mitochondrial biology.
RESULTS
Muscle-Specific ECT KO Mice
To generate mice with ECT-deficient muscle, we ablated exon 2
from the Pcyt2 gene, which encodes ECT, using the Cre-LoxP
system (Leonardi et al., 2009). The selective deletion of Pcyt2
in muscle was verified by genotyping muscle and a selection of
other tissues (Figure 1A). Only a single band of 406 bp was de-Ctected in the liver and kidney from both the Pcyt2fl/fl/Mck-
Cre0/0 and Pcyt2fl/fl/Mck-Cre+/0 mice, showing the presence of
only the floxed ECT gene. In contrast, muscle from Pcyt2fl/fl/
Mck-Cre+/0 mice primarily expressed the 207-bp band corre-
sponding to removal of exon 2 from Pcyt2 (Figure 1A). Further
confirmation of the deletion of Pcyt2 in muscle is demonstrated
by the95% reduction in Pcyt2mRNA, ECT protein, and activity
in Pcyt2fl/fl/Mck-Cre+/0 mice (Figures 1B–1D). The residual
expression and activity is likely due to the presence of additional
cell types other than muscle in the quadriceps (Bru¨ning et al.,
1998). We then examined whether deletion of Pcyt2 altered the
expression of enzymes in compensating pathways. The protein
content of phosphocholine cytidylyltransferase (Pcyt) 1a and
1b, enzymes involved in phosphatidylcholine (PtdCho) synthe-
sis, was not altered, while elimination of the CDP-ethanolamine
pathway caused a 2-fold increase in the protein and mRNA con-
tent of phosphatidylserine decarboxylase (PSD), an alternate
route for PtdEtn synthesis, which is localized to mitochondrial
membranes (Figures 1E–1G). Phosphatidylserine synthase 1
(Ptdss1) and 2 (Ptdss2) mRNA expression was normal in ECT-
deficient muscle (Figure 1G).ell Metabolism 21, 718–730, May 5, 2015 ª2015 Elsevier Inc. 719
Figure 2. Body Composition of Control and Muscle-Specific ECT KO Mice
(A) Body mass (n = 56 for control; n = 52 for ECT-deficient).
(B) Naso-anal length of control (n = 11) and ECT KO mice (n = 5).
(C) Fat mass (n = 56 for control; n = 52 for ECT-deficient).
(D) Lean mass (n = 56 for control; n = 52 for ECT-deficient).
(E) Quadriceps mass (n = 47 for control; n = 36 for ECT-deficient).
(F) Gastrocnemius mass (n = 47 for control; n = 36 for ECT-deficient).
(G) Tibialis anterior (TA) mass (n = 47 for control; n = 36 for ECT-deficient).
(H) The gross appearance of muscles from control and ECT KO mice.
(I) Total fiber number in TA muscles (n = 5).
(J) Average Feret’s minimal diameter of fibers from TA muscles (n = 4).
(K) Cross section of dystrophin-stained TA muscle from control and ECT KO mice (403 magnification).
(L) Representative image of TA muscle showing myosin heavy chain expression.
(M) Quantitative analysis of fiber type distribution. Data are mean ± SEM. For the individual muscle data, the combined mass of both muscles is presented.
*p < 0.05; ****p < 0.0001.General Characteristics
Muscle-specific ECT KO mice appeared outwardly normal with
no change in body mass or naso-anal length (Figures 2A and
2B). While no difference in fat mass (Figure 2C) was found, lean
mass was reduced in muscle-specific ECT KO mice (Figure 2D).
To determine the basis of this difference, the weights of a variety
of hindlimb muscles were assessed. Quadriceps, gastrocne-
mius, and tibialis anterior (TA) mass were all reduced by 25%–
30% in ECT-deficient mice (Figures 2E–2G). Importantly, this
phenotype was attributed to the loss of ECT as opposed to
non-specific effects of expression of Cre or the floxed Pcyt2
gene as lean mass and quadriceps mass were not different be-720 Cell Metabolism 21, 718–730, May 5, 2015 ª2015 Elsevier Inc.tween the floxed control animals, Mck-Cre control mice
(Pcyt0/0/Mck-Cre+/0), or wild-type control mice (Pcyt0/0/Mck-
Cre0/0; Figures S1A and S1B). In addition to being smaller, the
musculature of ECT-deficient mice had a marked increase in
red coloration (Figure 2H). Histological analysis of the TA muscle
revealed that the reduction in muscle mass in the ECT KO mice
was not caused by changes in myofiber number (Figure 2I), but
was due to a reduction in myofiber size (Figures 2J and 2K). In
addition, the TA muscle from the ECT KO mice exhibited a
modest shift in myosin heavy chain (MHC) isoform expression
with a reduction in the number of MHCIIb fibers, and an increase
in MHCIIx-expressing fibers (Figures 2L and 2M).
Figure 3. Lipid Handling in ECT-Deficient Muscle
(A and B) (A) Lipid content and (B) total fatty acid methyl ester (FAME) composition of control (n = 3) and ECT-deficient quadriceps muscle (n = 3).
(C) DG content in quadriceps of control (n = 6) and ECT KO mice (n = 6).
(D) DG species in control (n = 28) and ECT-deficient muscle (n = 28).
(E) Membrane-associated DG in muscle from control (n = 8) and ECT KO mice (n = 7).
(F) Palmitate oxidation in homogenates from control (n = 4) and ECT KO mice (n = 8).
(G–J) (G) Skeletal muscle palmitate uptake, (H) esterification into TG, (I) DG, and (J) oxidation (n = 7 for control; n = 11 for ECT KO). Data aremean ± SEM. *p < 0.05;
**p < 0.01; ***p < 0.001.Lipid Metabolism
The ECT-deficient muscles had a significant imbalance in the
levels of themajor lipid classes (Figure 3A). The content of PtdEtn
was 22% lower than in control animals, while there was no differ-
ence inPtdCho in theKOcomparedwith controlmice (Figure 3A).CCholesterol was increased almost 90%, and TG was elevated by
150% in the ECT-deficient muscles (Figure 3A). The overall FA
composition was also different in the ECT-deficient muscle (Fig-
ure 3B), with substantial increases in 16:0, 18:1, 18:2, and 20:4,
and a reduction in 22:6. In addition, total DG content was aboutell Metabolism 21, 718–730, May 5, 2015 ª2015 Elsevier Inc. 721
Figure 4. The Phospholipid Molecular Species Composition of ECT-Deficient Muscle
(A–C) The molecular species composition of (A) PtdEtn, (B) PtdCho, and (C) PtdSer. The molecular species fingerprints are of a typical control and ECT-deficient
muscle and are representative of threemice per genotype. The identification of the primary phospholipid molecular species in each of themajor peaks was based
on the fatty acid composition and the preponderance of saturated fatty acids in the 1-position and unsaturated fatty acids in the 2-position of phospholipids.2-fold higher in ECT-deficient muscle (Figure 3C). The FA
composition of DG was dramatically altered in ECT-deficient
muscle with 2- to 3-fold increases in 16:0-, 18:1-, and 18:2-con-
taining DG species (Figure 3D). Furthermore, membrane-associ-
ated DG was 2-fold higher in ECT-deficient muscle (Figure 3E).
The changes in lipid composition were associated with an in-
crease in SREBP1c (Srebf1) mRNA, while the expression of other
genes involved in lipid synthesis including Dgat1, Dgat2, Fasn,
and Scd1 (Figure S2A) was unchanged. Deletion of ECT also
caused significant alterations in FA handling, with ECT-deficient
muscle exhibiting an increase in FA oxidation in a muscle ho-
mogenate preparation (Figure 3F). Furthermore, in an intact
ex vivo system, rates of FA uptake and esterification into TG
and DG were elevated in ECT-deficient muscle (Figures 3G–3I).
Ex vivo FA oxidation was also increased in muscle from ECT
KO mice (Figure 3J), but was not associated with any change
in the expression of Cd36 or Cpt1b (Figure S2A). Muscle
glycogen was elevated in ECT-deficient muscle (Figure S2B),
consistent with observations demonstrating that when FA oxida-
tion is increased inmuscle, glucose is diverted away from glycol-
ysis and pyruvate oxidation toward glycogen storage (Hoehn
et al., 2010; Randle et al., 1963).
Phospholipid Composition
Elimination of the CDP-ethanolamine pathway and subsequent
reliance on the mitochondrial PSD pathway for PtdEtn synthesis
led to dramatic changes in the composition of the major phos-
pholipids. There was a pronounced difference in the PtdEtn
composition in ECT-deficient muscle (Figure 4A). (18:0/22:6)722 Cell Metabolism 21, 718–730, May 5, 2015 ª2015 Elsevier Inc.PtdEtn was the most abundant species in controls, and was
almost absent in muscle from the ECT KO mice. (18:0/20:4)
PtdEtn was the predominant species in the ECT-deficient mus-
cle with lower amounts of (18:0/22:6)PtdEtn. Overall, the PtdEtn
in the ECT-deficient muscle was enriched in species containing
18:0 paired with a polyunsaturated FA and deficient in species
containing 16:0 pairedwith a polyunsaturated FA. Although there
were no significant changes in the amount of PtdCho, there were
differences in the PtdCho species (Figure 4B). (16:0/18:1)PtdCho
and (16:0/22:6)PtdCho were the most prevalent species in the
controls. In the muscle-specific ECT KO mice there was a
decrease in the abundance of PtdCho molecular species con-
taining 22:6 leading to (16:0/18:2)PtdCho becoming the most
abundant species. Phosphatidylserine (PtdSer) was dominated
by (18:0/22:6)PtdSer in both control and ECT-deficient muscle,
constituting about 80% of PtdSer in controls, but only about
30% in ECT-deficient muscle (Figure 4C). In addition, the notable
difference in the PtdSer pool in muscle of the ECT KO mice
was a higher level of species with 16:0. These findings demon-
strate that inactivation of the CDP-ethanolamine pathway in
muscle not only influences the composition of PtdEtn, but also
has a major impact on the molecular species of PtdCho and
PtdSer.
Mitochondrial Content Is Increased in ECT-Deficient
Muscle
The increased red coloration of the ECT-deficient muscle
together with the elevated rates of FA oxidation suggest that
mitochondrial content is increased in muscle from ECT KO
mice. Indeed, electron microscopy (Figure 5A) demonstrated an
increase in mitochondrial density in the KO mice. Furthermore,
the expression of complexes II and V of the electron transport
chain (Figure 5B) as well as the intensity of succinate dehydroge-
nase (SDH) staining (Figure 5C) was elevated in ECT-deficient
muscle. We therefore examined whether mitochondrial biogen-
esis was increased by determiningmitochondrial protein synthe-
sis in vivo using heavy water (2H2O) labeling. Body water enrich-
ment of 2H2O (Figure S2C) remained constant at6%over the 4-
week labeling period. The ECT KO mice exhibited an increase in
mitochondrial protein synthesis (Figure 5D), demonstrating that
the increase inmitochondrial content was due to enhancedmito-
chondrial biogenesis. Consistent with these findings, cardiolipin,
a mitochondrial-specific lipid, was increased in ECT-deficient
muscle (Figure 5E), as were citrate synthase and b-HAD activity
(Figures 5F and 5G). Mitofusion 2 and PINK1 protein levels were
not changed (Figure S2E), suggesting that alterations in mito-
chondrial fusion or mitophagy were not responsible for the in-
crease in mitochondrial content in ECT-deficient muscle. We
next examined whether this was associated with changes in
known regulators of mitochondrial biogenesis. The activity of
AMP kinase (AMPK) was not affected by ECT deletion (Fig-
ure S2D), nor were the protein levels of PGC1a or cytochrome
c oxidase subunit IV (COX4; Figure 3H). However, mitochondrial
transcription factor A (TFAM) protein was 70% higher in ECT-
deficient muscle (Figure 3H). Interestingly, the mRNA expression
of PGC1a (Ppargc1a), Tfam, and Cox4 were actually reduced by
50% in ECT-deficient muscle (Figure S2A). In contrast, mito-
chondrial fission 1 protein (Fis1) was increased, while PGC1b
(Ppargc1b), PPARa (Ppara), PPARd (Ppard), and mitofusin 2
(Mfn2) were not altered (Figure S2A). A link between PtdEtn
and calcium homeostasis in muscle has been reported (Funai
et al., 2013), and given that activation of calcium signaling has
been associated with mitochondrial biogenesis, the phosphory-
lation status of calcium/calmodulin-dependent protein kinase II
(CaMKII) was examined. No differences in CaMKII protein or
phosphorylation were found between control and ECT-deficient
muscle (Figure S2F). As DG can activate protein kinase D (PKD) 1
(Sundram et al., 2011), a serine-threonine kinase that when over-
expressed drives an oxidative phenotype in muscle (Kim et al.,
2008), we examined whether the increased mitochondrial con-
tent in ECT-deficient muscle could be related to DG-induced
activation of PKD1. However, PKD1 phosphorylation was
reduced in ECT KO mice, which appeared to be due to a corre-
sponding reduction in total PKD1 protein (Figure S2G); thus, the
ratio of phosphorylated-to-total PKD1 remained unchanged.
Functionally, the increase in mitochondrial content in ECT-defi-
cient muscle was associated with enhanced respiratory capacity
as shown by an increase in oxygen consumption rates in the
presence of complex I and II substrates (Figure 5I). Furthermore,
endurance exercise capacity was enhanced in ECT KO mice
(Figure 5J). We next investigated whether the increased FA
oxidative capacity of ECT-deficient muscle would influence
whole-body substrate utilization during exercise. Oxygen con-
sumption was similar between genotypes (Figure 5K), but the
RER was lower in the muscle-specific ECT KO mice demon-
strating an increased reliance on fat oxidation during exercise
(Figure 5L). Elimination of the CDP-ethanolamine pathway
also had a significant impact on the mitochondrial phospholipidCprofile (Figure S4). Similar to whole muscle, (18:0/22:6)PtdEtn
was the most abundant species in mitochondria from control
muscle, but was dramatically reduced in mitochondria
from ECT-deficient muscle. The most predominant PtdEtn
species in mitochondria from ECT-deficient muscle were (18:0/
18:2) and (18:0/20:4)PtdEtn. In addition, mitochondria from
the ECT KO mice contained a larger proportion of PtdEtn
containing 16:0 and 18:0 FAs. In contrast, the mitochondrial
PtdCho profile was similar between control and ECT-deficient
mice. Interestingly, PtdCho in mitochondria from both the
control and ECT KO mice was found to be lacking in polyunsat-
urated FAs.
Energy Expenditure and Insulin Sensitivity AreNormal in
Muscle-Specific ECT KO Mice
Despite the increase in muscle oxidative capacity in ECT KO
mice, whole-body oxygen consumption, substrate utilization,
and food intake were similar to control animals (Figures 6A–
6C). In addition, physical activity levels were comparable be-
tween the control and ECT KO mice, ruling out the possibility
that the increase in mitochondria was due to changes in activity
levels (Figure 6D). To determine whether the increase in muscle
lipid content, as well as the changes in the composition of the
phospholipids in ECT-deficient muscle, was associated with
altered insulin sensitivity, euglycemic hyperinsulinemic clamps
were performed. Glucose levels were matched in both strains
and were clamped at basal levels (Figure 6E). The glucose infu-
sion rate was identical between strains (Figure 6F) as were the
plasma insulin levels under fasting and clamp conditions (Fig-
ure 6G), demonstrating that insulin sensitivity was not impaired
in ECT KO mice. Endogenous glucose production under basal
and clamped conditions was not different between strains (Fig-
ures 6H and 6I), and as such, percent suppression of endoge-
nous glucose production was similar (85% ± 9% versus 72% ±
7% for control and muscle-specific ECT KO mice, respectively;
p > 0.05). Deletion of ECT from muscle had no effect on periph-
eral glucose disposal (Figure 6J) or muscle glucose uptake
(Figures 6K and 6L). Accumulation of lipids, specifically DG, is
proposed to cause muscle insulin resistance via activation of
protein kinase (PKC) q (Griffin et al., 1999; Kim et al., 2004).
Despite elevated DG in ECT-deficient muscle, we failed to
detect any change in membrane-bound PKCq or its phosphory-
lation status (Figure S4). Plasma free fatty acids (FFAs) were
lower in the ECT KO compared with the control mice prior to
clamp, and were suppressed to levels observed in control
mice under clamp conditions (Figure 6M). Thus, despite marked
lipid accumulation and striking alterations in the phospholipid
composition, insulin sensitivity was preserved in ECT-deficient
muscle.
Muscle Lipid Content and Oxidative Capacity Are Not
Altered by ECT Overexpression
To determine whether overexpression of ECT alters muscle
lipids and oxidative capacity, a recombinant AAV6 vector ex-
pressing ECT was administered systemically to C57Bl/6 mice.
As expected, ECT protein and activity in quadriceps muscle
were increased, while there was no effect in liver and adipose
tissue (Figures S5A and S5B). Despite the increase in ECT
activity, there was no change in body mass, quadriceps mass,ell Metabolism 21, 718–730, May 5, 2015 ª2015 Elsevier Inc. 723
(legend on next page)
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Figure 6. Energy Metabolism and Insulin Sensitivity in Muscle-Specific ECT KO Mice
(A–D) (A) VO2, (B) RER, (C) 24-hr food intake, and (D) physical activity levels (n = 12 per group). The dark phase is represented by the shaded area.
(E and F) (E) Blood glucose levels and (F) glucose infusion rates during the euglycemic hyperinsulinemic clamp.
(G) Plasma insulin prior to and at the end of the clamp.
(H and I) (H) The endogenous rate of appearance (EndoRa) of glucose under basal and (I) clamp conditions.
(J) The rate of glucose disappearance (Rd) during the euglycemic hyperinsulinemic clamp.
(K and L) (K) Glucose uptake into the TA and (L) quadriceps muscle.
(M) Basal and clamp FFA levels. Data are mean ± SEM. For clamp data, n = 12 for control; n = 15 for ECT-deficient. *p < 0.05.muscle lipid content, or oxidative enzyme activity (Figures
S5C–S5H).
Muscle-Specific ECTKOMice AreNot Protected against
Diet-Induced Obesity and Glucose Intolerance
It has been suggested that enhanced muscle oxidative capacity
may protect against the development of lipid-induced insulinFigure 5. Mitochondrial Biogenesis and Oxidative Capacity Are Increa
(A) Electron micrograph of extensor digitorum longus muscle from control and E
(B) The expression of oxidative phosphorylation proteins in Complex I–V of the e
(C) SDH staining of cross-sections from TA muscle of control and ECT KO mice.
(D) Mitochondrial protein synthesis (n = 9 for control; n = 5 for ECT KO).
(E) Cardiolipin content (n = 28 per group).
(F and G) (F) Citrate synthase and (G) b-HAD activity in quadriceps (Quad; n = 19
(H) Representative immunoblot and quantitation of PGC1a, COX4, and TFAM pr
(I) Basal and substrate-driven oxygen consumption rates in muscle from control
(J) Endurance exercise capacity in control (n = 6) and muscle-specific ECT KO m
(K and L) (K) VO2 and (L) RER during exercise (n = 6 per group). Data are mean ±
substrate p < 0.05.
Cresistance (Phielix et al., 2012). We therefore placed control
and ECT KO mice on a high-fat diet (HFD) and examined their
metabolic responses. Body mass, weight gain, and fat mass
were identical in control and ECT-deficient mice in response to
4 weeks of the HFD (Figures 7A–7E). Muscle TG (4-fold) and
DG (2-fold) were elevated in ECT-deficient muscle (Figures 7F
and 7G), as were FA oxidation rates (Figure 7H) and citratesed in ECT-Deficient Muscle
CT KO mice.
lectron transport chain (n = 4 for both genotypes).
per group) and gastrocnemius (Gastroc; n = 15 per group).
otein (n = 8 per group).
(n = 12) and ECT KO mice (n = 8).
ice (n = 8).
SEM. *p < 0.05; **p < 0.01. ymain effect for genotype p < 0.05; zmain effect for
ell Metabolism 21, 718–730, May 5, 2015 ª2015 Elsevier Inc. 725
Figure 7. The Effect of a HFD on Metabolic Responses in Muscle-Specific ECT KO Mice
(A–E) Control and muscle-specific ECT KO mice were fed a HFD for 4 weeks, and body mass (A), weight gain (B), fat mass (C), and epididymal (D) and sub-
cutaneous (E) fat mass were determined.
(F and G) Muscle TG (F) and DG (G) content were determined.
(H) Palmitate oxidation rates were determined in isolated extensor digitorum longus muscles ex vivo.
(I) Citrate synthase activity in the quadriceps muscle.
(J–L) Plasma FFA (J), triglyceride (K), and insulin (L) levels.
(M) Blood glucose levels following a glucose tolerance test.
(N and O) VO2 (N) and RER (O). The dark phase is represented by the shaded area. Control n = 5; muscle-specific ECT KO n = 9. Data are mean ± SEM. *p < 0.05;
***p < 0.001.synthase activity (Figure 7I). However, FFAs, triglycerides, and
insulin were not different between control and ECT KO mice
(Figures 7J–7L). Even though ECT-deficient muscle exhibited
marked lipid accumulation, glucose tolerance was similar in
ECTKOand controlmicewhenmaintained on aHFD (Figure 7M).
While whole-body oxygen consumption was not different be-
tween genotypes (Figure 7N), RER was lower in the ECT KO
mice demonstrating that the rates of whole-body fat oxidation
were higher compared with control mice (Figure 7O). We also
examined whether ECT protein levels would be affected by con-
sumption of a HFD; however, the HFD had no effect (Figure S6).
Collectively, these observations show that despite the fact that
ECT-deficient mice display increased FA oxidation, they are
not protected from HFD-induced muscle lipid accumulation or
weight gain.726 Cell Metabolism 21, 718–730, May 5, 2015 ª2015 Elsevier Inc.DISCUSSION
The CDP-ethanolamine pathway has emerged as an important
regulator of hepatic lipid homeostasis (Fullerton et al., 2009;
Leonardi et al., 2009); however, its role in skeletal muscle had
not been studied. Our data provide novel and compelling evi-
dence that the CDP-ethanolamine pathway plays a critical
role in regulating muscle lipid homeostasis. ECT-deficient mus-
cle was characterized by marked DG and TG accumulation and
significant alterations in phospholipid composition, but these
changes did not alter whole-body or muscle insulin sensitivity.
In addition, elimination of the CDP-ethanolamine pathway
in muscle had a number of surprising and unanticipated
effects. The muscle-specific ECT KO mice exhibited smaller
muscles that had increased mitochondrial content. This was
associated with enhanced skeletal muscle oxidative capacity
and improved endurance performance. These findings high-
light important, yet unexpected, roles of the CDP-ethanol-
amine pathway in regulating muscle function and substrate
metabolism.
The absence of PtdEtn synthesis via the CDP-ethanolamine
pathway disrupted skeletal muscle lipid homeostasis resulting
in accumulation of both TG and DG. The utilization of DG for
phospholipid synthesis at the ER is reduced due to the absence
of ECT expression, and, consistent with the findings in cultured
cells (Jackowski et al., 2000) and ECT-deficient liver (Fullerton
et al., 2009; Leonardi et al., 2009), DG is redirected to TG synthe-
sis. The increase in DG esterification and lipid storage in ECT-
deficient muscle was further facilitated by elevated rates of FA
uptake. Furthermore, consistent with previous reports linking
the activation of SREBP with lipid accumulation in tissues lack-
ing the CDP-ethanolamine pathway (Leonardi et al., 2009; Lim
et al., 2011), the transcript levels of SREBP were upregulated
in ECT-deficient muscle that may have also contributed to the
increased DG and TG content.
Lipids, especially DG, are proposed to play a key role in the
development of muscle insulin resistance (Itani et al., 2002; Li
et al., 2004; Perseghin et al., 1999; Yu et al., 2002). Given the
changes in lipid homeostasis observed in ECT-deficient muscle,
we hypothesized that ECT KO mice would develop insulin resis-
tance via activation of the DG-sensitive PKCq, an established
mediator of lipid-induced insulin resistance in muscle (Itani
et al., 2002; Li et al., 2004; Yu et al., 2002). Contrary to our hy-
pothesis, muscle insulin sensitivity remained intact in ECT KO
mice, and despite significant DG accumulation, we did not
detect any change in the activation status of PKCq. These find-
ings challenge the prevailing view that DG accumulation is a
requisite factor in the development of skeletal muscle insulin
resistance (Erion and Shulman, 2010). However, the relationship
between DG accumulation and insulin action is complex,
demonstrated by the fact that elevated DG levels have been
found in muscle of highly trained athletes who are remarkably in-
sulin sensitive (Amati et al., 2011). Moreover, recent studies have
highlighted that in addition to the total DG, other factors including
subcellular localization, FA composition, as well as the type of
DG stereoisomer stored (i.e., sn-1,2 DG, sn-1,3 DG, or sn-2,3
DG) may influence this relationship (Bergman et al., 2012; Eich-
mann et al., 2012). Our finding that muscle insulin sensitivity
was unaffected, despite an increase in membrane-associated
DG, sheds new light on this relationship and challenges the
concept that muscle insulin resistance links specifically to alter-
ations in membrane DG content. Together, these findings pro-
vide direct evidence that increases in lipid content, localization,
and specific molecular species do not necessarily cause muscle
insulin resistance, and that using general measures of lipid con-
tent as a surrogate readout for insulin resistance is too simplistic.
The phospholipid content and composition of ECT-deficient
muscle was also altered, with ECT KO mice exhibiting perturba-
tions in the composition of all major phospholipid pools as well
as a 22% reduction in PtdEtn content. However, as the CDP-
ethanolamine pathway is considered to be the major route of
PtdEtn synthesis in mammals (Bleijerveld et al., 2007; Sundler
et al., 1974), it is intriguing that deletion of ECT from muscle
caused such a modest reduction in PtdEtn content. Thus, itCseems that the PSD pathway is able to compensate for reduced
PtdEtn synthesis via the CDP-ethanolamine pathway in order to
maintain relatively high levels of PtdEtn in ECT-deficient muscle.
Consistent with this notion, PSD protein and mRNA were
increased in ECT-deficient muscle. Furthermore, PtdEtn in the
control muscle largely reflects the composition of the PtdSer
pool (compare Figures 4A and 4C), suggesting that the PSD
pathway is the primary source for PtdEtn in muscle. However,
if this were the case, one would expect a dominance of (18:0/
22:6)PtdEtn in the ECT-deficient muscle as well, but the data
do not support this conclusion. Comparison of the control and
ECT-deficient PtdEtn profiles (Figure 4A) suggests that the
(18:0/22:6)PtdEtn is replaced by an abundance of (18:0/20:4)
PtdEtn when the ECT pathway is not operational. Post de novo
phospholipid remodeling either by CoA-dependent acyltransfer-
ase or CoA-independent transacylase activities, together with
the availability of the essential FA linoleate (18:2n-6) in the circu-
lation, may be responsible for the abundance of (20:4)PtdEtn in
the ECT-deficient muscle (for reviews see Shindou et al., 2009;
Shindou and Shimizu, 2009). Linoleate is the precursor of arach-
idonic acid (20:4), which is liberated for eicosanoid synthesis
and, if not utilized for this purpose, can accumulate in PtdEtn.
These data contrast to the PtdEtn profile in ECT-deficient liver
(Leonardi et al., 2009) where there is no evidence of phospholipid
remodeling, and the PtdEtn pool is a clear reflection of the FA
distribution in PtdSer.
The most surprising finding of the current study was the in-
crease in mitochondrial biogenesis in ECT-deficient muscle.
This was associated with an enhanced capacity for FA oxidation,
reflected by an increase in muscle FA oxidation as well as whole-
body rates of fat oxidation during exercise, andwas coupledwith
an increase in endurance exercise capacity in the ECT KO mice.
When placed on a HFD, ECT KO mice had elevated rates of
whole-body fat oxidation; however, this did not prevent HFD-
induced lipid accumulation, nor did it alter glucose tolerance.
Furthermore, as the increase in muscle oxidative capacity was
not associated with a change in energy expenditure, ECT-defi-
cient mice gained weight at the same rate as control mice
when fed a HFD. These findings contrast those in Pcyt2+/
mice that have an impaired ability to oxidize FAs and develop
obesity and glucose intolerance (Fullerton et al., 2009). The
reason for these discrepancies is not clear, but may be related
to the fact that in addition to muscle, the Pcyt2+/ mice had
reduced ECT activity in other important metabolic tissues,
particularly the liver, which may account for divergent effects
on whole-body metabolism (Fullerton et al., 2009). However, it
is worth noting that, similar to our findings, liver-specific ECT
KO mice did not develop obesity, despite exhibiting severe he-
patic steatosis (Leonardi et al., 2009).
Despite our extensive studies examining the mechanism(s)
responsible for the increase in mitochondrial biogenesis and
oxidative capacity of ECT-deficient muscle, they are not
completely resolved. The modest shift in MHC isoform expres-
sion from IIb to IIx in ECT-deficient muscle is likely to play
some role in contributing to this phenotype as the oxidative
capacity of IIx fibers is higher than that of IIb (Bloemberg and
Quadrilatero, 2012). To try to understand the mechanisms
responsible, we examined regulators of mitochondrial biogen-
esis and fiber type determination. While there was no changeell Metabolism 21, 718–730, May 5, 2015 ª2015 Elsevier Inc. 727
in AMPK or PPAR expression, TFAM protein was increased
despite the fact that PGC1a protein was unaltered. It is inter-
esting to note, however, that while an increase in TFAM expres-
sion causes an upregulation of mitochondrial DNA copy number,
it does so without increasing respiratory capacity or mitochon-
drial content (Ekstrand et al., 2004), suggesting that factors in
addition to an increase in TFAM are likely to be involved. Recent
work has identified a role for PKD1, a DG-sensitive kinase, in
regulating the oxidative phenotype in muscle (Kim et al., 2008).
Activation of PKD1 leads to phosphorylation and nuclear export
of class II histone deacetylases, relieving repression on myocyte
enhancer factor-2, which drives an oxidative phenotype (Kim
et al., 2008). As DG content was increased in ECT-deficient mus-
cle, we examined whether activation of PKD1 could contribute to
the increase in oxidative capacity. Contrary to our hypothesis,
the phosphorylation status of PKD1 was actually lower in ECT-
deficient muscle, but this could be due to the fact that total
PKD1 levels were also reduced. It is possible that the reliance
on the PSD pathway as the sole route for PtdEtn synthesis in
ECT-deficient muscle may play a role in mediating the increase
in mitochondrial biogenesis and oxidative capacity. PSD is local-
ized tomitochondria; therefore, the absolute dependence on this
pathway in order to maintain near-normal levels of PtdEtn in
muscle lacking the CDP-ethanolamine pathway may provide a
stimulus to increase mitochondrial biogenesis. Such an adapta-
tion would be expected to enhance the capacity of PtdEtn syn-
thesis via the PSD pathway. Unfortunately, little is known about
the role of the PSD pathway in mammalian biology; however,
given that PSD deficiency disrupts mitochondrial function (Tas-
seva et al., 2013), we speculate that the upregulation of this
pathway may somehow contribute to the increase in mitochon-
drial biogenesis and enhanced oxidative capacity of ECT-defi-
cient muscle.
The synthesis of membrane phospholipids, including PtdEtn,
is important for growth (Pavlovic and Bakovic, 2013; Tasseva
et al., 2013). Indeed, depletion of mitochondrial PtdEtn caused
by silencing PSD impairs cell growth (Tasseva et al., 2013).
Furthermore, the Pcyt2 gene is induced by growth factors (Zhu
et al., 2008), and global elimination of ECT is embryonic lethal
(Fullerton et al., 2007), providing additional evidence that the
CDP-ethanolamine pathway is critical for normal growth and
development. However, it is interesting to note that no growth
and developmental defects have been reported in Pcyt2+/
mice (Fullerton et al., 2009), while elimination of the CDP-
ethanolamine pathway in liver did not affect proliferation, differ-
entiation, or survival of hepatocytes (Leonardi et al., 2009). In
contrast, we show that muscle-specific ECT KO mice exhibit
smaller fibers and have less lean mass compared with control lit-
termates. This is an intriguing finding and suggests that the CDP-
ethanolamine pathway is required for the development and
maintenance of skeletal muscle mass. Further work will be
required to examine the mechanisms responsible for this pheno-
type and to determine whether the CDP-ethanolamine pathway
is disrupted in conditions associated with accelerated muscle
wasting.
We have established that the CDP-ethanolamine pathway is
required for the maintenance of normal muscle lipid homeosta-
sis. Deletion of ECT not only altered the molecular species
composition of the major phospholipids in muscle, but also728 Cell Metabolism 21, 718–730, May 5, 2015 ª2015 Elsevier Inc.caused marked lipid accumulation. However, contrary to our hy-
pothesis, the increase in DG content did not influence muscle in-
sulin sensitivity, demonstrating that accumulation of DG is not
sufficient to cause muscle insulin resistance. The elimination of
the CDP-ethanolamine pathway also had unexpected effects
including an increase in skeletal muscle mitochondrial biogen-
esis and a reduction in muscle mass. These findings not only un-
derscore the importance of the CDP-ethanolamine pathway in
regulating lipid metabolism, but also reveal a new and intriguing




Mice lacking functional ECT expression in muscle were generated by crossing
Pcyt2 floxed (Pcyt2fl/fl) mice with mice expressing Cre recombinase under the
control of themuscle creatine kinase promoter (Mck-Cre) (Bru¨ning et al., 1998).
A description of the construct design and generation ofPcyt2fl/fl mice has been
detailed elsewhere (Leonardi et al., 2009). Pcyt2fl/fl mice were mated with
Pcyt2fl/fl, Mck-Cre+/0 mice, generating mice with either normal levels of ECT
in muscle (Pcyt2fl/fl, Mck-Cre0/0) or ECT-deficient muscle (Pcyt2fl/fl, Mck-
Cre+/0). For all experiments, floxed littermates (Pcyt2fl/fl, Mck-Cre0/0) were
used as controls. Unless otherwise stated, all experiments were conducted
on 18-week-old male mice maintained on a standard laboratory chow diet
(5% calories from fat, Specialty Feeds) and housed at 22C ± 1C on a
12:12-hr light-dark cycle, with free access to food and water. To increase
ECT activity in muscle, a recombinant AAV vector expressing ECT was admin-
istered systemically to C57Bl/6 mice (see Supplemental Experimental Proce-
dures for more detail). For the HFD studies, 6-week-old mice were fed a HFD
(42% calories from fat, Specialty Feeds) for 4 weeks. All procedures were
approved by the Alfred Medical Research and Education Precinct Animal
Ethics Committee and Monash Animal Research Platform Animal Ethics
Committee.
Body Composition and Muscle Histology
Fat and lean mass were determined using the EchoMRI 4-in-1 (Echo Medical
Systems). Mice were then anesthetized with sodium pentobarbital (60 mg/kg),
naso-anal length was determined, and muscles (extensor digitorum longus
[EDL], TA, gastrocnemius, and quadriceps) were dissected, weighed, frozen
in liquid nitrogen, or prepared for histological analysis including electron mi-
croscopy studies (described in Supplemental Experimental Procedures).
Lipid Metabolism
Lipids were extracted using amodification of the Bligh and Dyer method (Bligh
and Dyer, 1959) optimized for lipid quantitation by the LipidMaps group (Iva-
nova et al., 2007). The amount of each major lipid class was determined using
flame-ionization mass detection (Leonardi et al., 2009). For some studies, TG
content was determined biochemically using a colorimetric assay kit (Triglyc-
erides GPO-PAP, Roche Diagnostics) (Bruce et al., 2007). Total DG was deter-
mined according to the enzymatic-radiometric methods of Preiss et al. (Preiss
et al., 1986). Analysis of membrane-associated DG was performed as previ-
ously described (Bruce et al., 2009). Cardiolipin content and the molecular
species of DG were determined by mass spectrometry (Bruce et al., 2012).
Phospholipid molecular species fingerprints of muscle and isolated mitochon-
dria were determined using previously described methods (Ivanova et al.,
2007; Krank et al., 2007; Leonardi et al., 2009). FA metabolism was assessed
in a homogenate preparation or isolated intact EDLmuscles (described in Sup-
plemental Information).
Metabolic Assessment
Glucose tolerance tests (1 g/kg lean bodymass glucose i.p.) were performed in
6-hr-fasted mice. Hyperinsulinemic euglycemic clamps were performed in
conscious, restrained mice as described in detail elsewhere (Bruce et al.,
2012). Plasma insulin was measured by ELISA (Millipore). FFAs were
measured by an enzymatic colorimetric assay (NEFA C kit; Wako Chemicals).
Plasma triglycerides were determined using a colorimetric assay kit (Triglycer-
ides GPO-PAP, Roche Diagnostics). Oxygen consumption (VO2), RER, and
physical activity levels were determined using a 12-chamber indirect calorim-
eter (Oxymax series, Columbus Instruments). Respiratory parameters were
measured in individual mice over a 24-hr period under a consistent environ-
mental temperature (22C) with ad libitum access to food and water. In vivo
mitochondrial biogenesis was determined by measuring mitochondrial protein
synthesis according to the methods of Miller and colleagues (Drake et al.,
2013), which are detailed in the Supplemental Information. Respiratory
capacity was determined in muscle biopsies using the Seahorse XF flux
analyzer (detailed in Supplemental Information). Exercise capacity was
determined by performing a treadmill run to exhaustion. Mice were familiarized
with the treadmill (Columbus Instruments) daily for 5 days prior to the test.
On the day of the test, mice were placed on the treadmill and allowed
to acclimate for 15 min before running at 16 m/min until exhaustion. After
1 week, mice performed a standardized 15-min run at 16m/min in an enclosed
treadmill (Columbus Instruments) to determine VO2 and RER by indirect
calorimetry.
Enzyme Activity Assays
ECT activity was assayed using [14C]phosphoethanolamine (American Radio-
labeled Chemicals) as a substrate (Fullerton et al., 2007; Leonardi et al., 2009).
Citrate synthase and b-HAD activity were determined using established
methods (Lowry and Passonneau, 1972; Srere, 1969). AMPK activity was
measured in lysates as previously described (Lee-Young et al., 2009).
Quantitative Real-Time RT-PCR
RNAwas isolated frommuscle using TRIzol (Invitrogen). Samples were reverse
transcribed, and gene expression analysis was performed by RT-PCR using
SYBR Green PCR Master Mix (Invitrogen). 18S or 36B4 were used as
house-keeping genes. The primers used are detailed in Table S1. The relative
quantification was calculated using the DDCt method, normalizing values to
littermate controls.
Western Blotting
Quadricepsmuscle was lysed, and protein (40 mg) was resolved by SDS-PAGE
(Bio-Rad Laboratories). After transfer to PVDF membranes, stain-free images
for total proteome visualization were collected, and membranes were blocked
in 5% BSA. After incubation with primary antibody (detailed in Table S2),
appropriate secondary antibodies were applied, and the immunoreactive pro-
teins were detected with enhanced chemiluminescence and quantified by
densitometry. Data was normalized to the loading control obtained from the
stain-free gel and was expressed as a relative change from the control group.
Analysis of membrane and cytosolic PKCq were performed as previously
described (Bruce et al., 2009).
Statistics
All data are presented as mean ± SEM. Data were analyzed by unpaired
Student’s t test or repeated-measures factorial ANOVA where appropriate.
For the ANOVA procedures, Newman-Keuls post hoc tests were used
to establish differences between groups. Statistical significance was set at
p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2015.04.001.
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